KKPCF.US Kaken Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals USA Stocks
26.00 USD
Close of Nov 15, 2026
22.16 26.35
Market cap
USD 985M
P/E
-
P/B
1.02x
ROE
10.3%
Dividend yield
4.60%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is KKPCF.US undervalued?

Graham number

The Graham number of Kaken Pharmaceutical Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kaken Pharmaceutical Co. Ltd fundamental analysis

No fundamental analysis for Kaken Pharmaceutical Co. Ltd yet.

Kaken Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kaken Pharmaceutical Co. Ltd

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc …

Full company profile